Immunotherapy with Valergen sublingual vaccines in asthmatics patients from Cabaiguan to Sancti Spiritus
Keywords:
mites, allergenic extract, sublingual immunotherapy, vaccines ValergenAbstract
Introduction: sublingual immunotherapy makes its way into allergological practice and numerous studies confirm its effectiveness and safety. Objective: to characterize the results with the use of Valergen sublingual vaccines in asthmatic patients of Cabaiguan municipality. Method: a descriptive-prospective investigation was conducted from January 2013 to December 2016 in patients diagnosed with intermittent bronchial asthma, persistent, slow and moderate. The universe was constituted by 467 patients. The sample was of 44 patients, of all ages and sexes, who met these conditions, were seen in consultation during the studied period and evaluated each patient after three years of treatment with immunotherapy. The data were obtained from the clinical records and the vaccination record of the allergy department. Results: female patients between 5-14 years (34.1%),and Dermatophagoide pteronyssinus was the mite with the highest sensitivity and use (45.4%), after 3 years of treatment, patients with a better control of their symptoms (72.7%), there were no adverse events (79.5%) in the patients, those presented were classified as local and mild systemic (20.5%). Conclusions: sublingual immunotherapy for bronchial asthma proved to be safe and clinically favorable in the patients.Downloads
Download data is not yet available.
References
1. González Marín AT, Cabrera Valldaura MC, González Iglesias A, González Iglesias L, Triana Toledo Y. Comportamiento de la sibilancia en niños menores de cinco años de la provincia Sancti Spíritus. Rev Inf Cient [en línea]. 2018 Jun; 97(3):538-547. [citado 12 Jun 2018]. Disponible en: http://www.revinfcientifica.sld.cu/index.php/ric/article/view/1932/
2. Li P, Li Q, Huang Z, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol [en línea]. 2014 [citado 26 Sept 2018; 4(10):796-801. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/alr.21397/abstract;jsessionid=48AB2D1DDACC0426FE8852B28C18D198.f03t03
3. Pellegrini Belinchon J, Miguel Miguel G, De Dios Martin B, Vicente Galindo E, Lorente Toledano F, et al. Study of wheezing and its risk factors in the first year of life in the Province of Salamanca, Spain. The EISL Study. Allergol Immunopathol (Madr) [en línea]. 2012 [citado 26 Sept 2018]; 40(3):164-71. Disponible en: http://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-linkresolver-study-wheezing-its-risk-factors-S0301054611002047
4. Corzo JL, Carrillo T, Pedemonte C, Plaza Martín AM, Martín Hurtado S, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol [en línea]. 2014 [citado 26 Sept 2018]; 24(3):154-61. Disponible en: http://www.jiaci.org/issues/vol24issue3/2.pdf
5. Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J [en línea] 2014 [citado 26 Sept 2018]; 7(1):21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192398/
6. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol [en línea]. 2006 May; 117(5):1021-35. [citado 26 Sept 2018]. Disponible en: http://www.sciencedirect.com/science/article/pii/S0091674906005185?via%3Dihub
7. Ferraris F, Beratarrechea A, Llera J, Marchetti M, Permanet G. Utilización de recursos y costos médicos directos de las enfermedades crónicas en una población pediátrica argentina. Arch Argent Ped [en línea]. 2011; 109(3):213–8. [citado 26 Sept 2018]. Disponible en: http://www.scielo.org.ar/pdf/aap/v109n3/v109n3a05.pdf
8. Rodríguez Santos O, Reyes Almaguer M. Eficacia y seguridad de la inmunoterapia sublingual en niños de 6 a 24 meses de edad con rinitis y asma bronquial sensibilizados a los ácaros domésticos. Vaccimonitor [en línea]. 2015; 24(2): 86-92. [citado 26 Sept 2018]. Disponible en: http://scielo.sld.cu/pdf/vac/v24n2/vac05215.pdf
9. Pagés Rubio C, Calderín Marín O, Morales Menéndez M. Vigilancia de la efectividad y seguridad de las vacunas VALERGEN en el tratamiento del asma. AMC [en línea]. 2016 Dic; 20(6):636-647. [citado 26 Sept 2018]. Disponible en: http://scielo.sld.cu/pdf/amc/v20n6/amc070616.pdf
10.Labrada Rosado A. Desarrollo a ciclo completo de las primeras vacunas estandarizadas de alérgenos de ácaros para la inmunoterapia en Cuba [Tesis]. La Habana: Instituto Superior de Ciencias Médicas; 2008. [citado 26 Sept 2018]. Disponible en: http://tesis.repo.sld.cu/145/2/Alexis_Labrada_.pdf
11.Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention. Chicago: GINA; 2016. [en línea] [citado 26 Sept 2018]. Disponible en: http://chicagoasthma.org/wp-content/uploads/2016/07/Whats-new-in-GINA-2016.pdf
12.Ross Peña A, Rodríguez Pérez J, Pérez Fabelo M, Sarduy Ramos CM. Eficacia diagnóstica de la prueba cutánea de Prick con extractos alergénicos de ácaros en pacientes asmáticos. AMC [en línea]. 2009 May-Jun [citado 26 Sept 2018]; 13(3):1-9. Disponible en: http://scielo.sld.cu/pdf/amc/v13n3/amc07309.pdf
13.Cuba. Minsap. Normas y procedimientos de trabajo del Sistema Cubano de Farmacovigilancia [en línea]. La Habana: MINSAP; 2011. Disponible en: http://files.sld.cu/cdfc/files/2012/10/normas-y-procedimientos-2012.pdf
14.Ciprandi G1, Incorvaia C, Dell'Albani I, Masieri S, Cavaliere C, Puccinelli P, et al. Characteristics of candidates for allergen immunotherapy. Allergy Rhinol (Providence) [en línea]. 2013 Summer [citado 26 Sept 2018]; 4(2):e77-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793117/
15.Potter PC, Baker S, Fenemore B, Nurse B. Clinical and cytokine responses to house dust mite sublingual immunotherapy. Ann Allergy Asthma Immunol [en línea]. 2015 Apr [citado 26 Sept 2018]; 114(4):327-34. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25661658
16.Trebuchon F, Lhéritier Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy [en línea]. 2014 Apr [citado 26 Sept 2018]; 4:15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047545/
2. Li P, Li Q, Huang Z, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol [en línea]. 2014 [citado 26 Sept 2018; 4(10):796-801. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/alr.21397/abstract;jsessionid=48AB2D1DDACC0426FE8852B28C18D198.f03t03
3. Pellegrini Belinchon J, Miguel Miguel G, De Dios Martin B, Vicente Galindo E, Lorente Toledano F, et al. Study of wheezing and its risk factors in the first year of life in the Province of Salamanca, Spain. The EISL Study. Allergol Immunopathol (Madr) [en línea]. 2012 [citado 26 Sept 2018]; 40(3):164-71. Disponible en: http://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-linkresolver-study-wheezing-its-risk-factors-S0301054611002047
4. Corzo JL, Carrillo T, Pedemonte C, Plaza Martín AM, Martín Hurtado S, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol [en línea]. 2014 [citado 26 Sept 2018]; 24(3):154-61. Disponible en: http://www.jiaci.org/issues/vol24issue3/2.pdf
5. Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J [en línea] 2014 [citado 26 Sept 2018]; 7(1):21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192398/
6. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol [en línea]. 2006 May; 117(5):1021-35. [citado 26 Sept 2018]. Disponible en: http://www.sciencedirect.com/science/article/pii/S0091674906005185?via%3Dihub
7. Ferraris F, Beratarrechea A, Llera J, Marchetti M, Permanet G. Utilización de recursos y costos médicos directos de las enfermedades crónicas en una población pediátrica argentina. Arch Argent Ped [en línea]. 2011; 109(3):213–8. [citado 26 Sept 2018]. Disponible en: http://www.scielo.org.ar/pdf/aap/v109n3/v109n3a05.pdf
8. Rodríguez Santos O, Reyes Almaguer M. Eficacia y seguridad de la inmunoterapia sublingual en niños de 6 a 24 meses de edad con rinitis y asma bronquial sensibilizados a los ácaros domésticos. Vaccimonitor [en línea]. 2015; 24(2): 86-92. [citado 26 Sept 2018]. Disponible en: http://scielo.sld.cu/pdf/vac/v24n2/vac05215.pdf
9. Pagés Rubio C, Calderín Marín O, Morales Menéndez M. Vigilancia de la efectividad y seguridad de las vacunas VALERGEN en el tratamiento del asma. AMC [en línea]. 2016 Dic; 20(6):636-647. [citado 26 Sept 2018]. Disponible en: http://scielo.sld.cu/pdf/amc/v20n6/amc070616.pdf
10.Labrada Rosado A. Desarrollo a ciclo completo de las primeras vacunas estandarizadas de alérgenos de ácaros para la inmunoterapia en Cuba [Tesis]. La Habana: Instituto Superior de Ciencias Médicas; 2008. [citado 26 Sept 2018]. Disponible en: http://tesis.repo.sld.cu/145/2/Alexis_Labrada_.pdf
11.Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention. Chicago: GINA; 2016. [en línea] [citado 26 Sept 2018]. Disponible en: http://chicagoasthma.org/wp-content/uploads/2016/07/Whats-new-in-GINA-2016.pdf
12.Ross Peña A, Rodríguez Pérez J, Pérez Fabelo M, Sarduy Ramos CM. Eficacia diagnóstica de la prueba cutánea de Prick con extractos alergénicos de ácaros en pacientes asmáticos. AMC [en línea]. 2009 May-Jun [citado 26 Sept 2018]; 13(3):1-9. Disponible en: http://scielo.sld.cu/pdf/amc/v13n3/amc07309.pdf
13.Cuba. Minsap. Normas y procedimientos de trabajo del Sistema Cubano de Farmacovigilancia [en línea]. La Habana: MINSAP; 2011. Disponible en: http://files.sld.cu/cdfc/files/2012/10/normas-y-procedimientos-2012.pdf
14.Ciprandi G1, Incorvaia C, Dell'Albani I, Masieri S, Cavaliere C, Puccinelli P, et al. Characteristics of candidates for allergen immunotherapy. Allergy Rhinol (Providence) [en línea]. 2013 Summer [citado 26 Sept 2018]; 4(2):e77-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793117/
15.Potter PC, Baker S, Fenemore B, Nurse B. Clinical and cytokine responses to house dust mite sublingual immunotherapy. Ann Allergy Asthma Immunol [en línea]. 2015 Apr [citado 26 Sept 2018]; 114(4):327-34. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25661658
16.Trebuchon F, Lhéritier Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy [en línea]. 2014 Apr [citado 26 Sept 2018]; 4:15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047545/
Published
2018-10-23
How to Cite
1.
Perdomo Pulido Y, González Marín Álvaro T, Sánchez Pérez E, Castro González V, González Iglesias Álvaro. Immunotherapy with Valergen sublingual vaccines in asthmatics patients from Cabaiguan to Sancti Spiritus. Rev Inf Cient [Internet]. 2018 Oct. 23 [cited 2025 Apr. 19];97(4):766-7. Available from: https://revinfcientifica.sld.cu/index.php/ric/article/view/2049
Issue
Section
Original Articles
